Oncogene- and tumor suppressor gene-mediated suppression of cellular senescence

Seminars in Cancer Biology

Volumn 21, Issue 6, 2011, Pages 367-376

  Larsson, Lars Gunnar ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

DDR; Myc; P53; PRb; Senescence

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; PROTEIN P16; PROTEIN P27; PROTEIN P53;

APOPTOSIS; CANCER GROWTH; CELL AGING; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL TYPE; CELLULAR STRESS RESPONSE; DNA DAMAGE; DNA METHYLATION; DNA REPAIR; DNA REPLICATION; DOWN REGULATION; GENE; GENE CLUSTER; GENE FUNCTION; GENE REPRESSION; GENE TARGETING; HUMAN; NONHUMAN; ONCOGENE; ONCOGENE MYC; P16 GENE; PRB GENE; PROTEIN TARGETING; REVIEW; TUMOR CELL; TUMOR SUPPRESSOR GENE;

CELL AGING; DNA DAMAGE; GENES, TUMOR SUPPRESSOR; HUMANS; ONCOGENES; OXIDATIVE STRESS;

EID: 82755186408     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2011.10.005     Document Type: Review

References (157)

1. Lowe S.W., Cepero E., Evan G. Intrinsic tumour suppression. Nature 2004, 432:307-315.
2. Campisi J., d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007, 8:729-740.
3. Collado M., Serrano M. Senescence in tumours: evidence from mice and humans. Nat Rev Cancer 2010, 10:51-57.
4. Kuilman T., Michaloglou C., Mooi W.J., Peeper D.S. The essence of senescence. Genes Dev 2010, 24:2463-2479.
5. Hayflick L., Moorhead P.S. The serial cultivation of human diploid cell strains. Exp Cell Res 1961, 25:585-621.
6. Blasco M.A. Telomere length, stem cells and aging. Nat Chem Biol 2007, 3:640-649.
7. Wright W.E., Shay J.W. Time, telomeres and tumours: is cellular senescence more than an anticancer mechanism?. Trends Cell Biol 1995, 5:293-297.
8. Serrano M., Lin A.W., McCurrach M.E., Beach D., Lowe S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997, 88:593-602.
9. Braig M., Lee S., Loddenkemper C., Rudolph C., Peters A.H., Schlegelberger B., et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 2005, 436:660-665.
10. Chen Z., Trotman L.C., Shaffer D., Lin H.K., Dotan Z.A., Niki M., et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005, 436:725-730.
11. Collado M., Gil J., Efeyan A., Guerra C., Schuhmacher A.J., Barradas M., et al. Tumour biology: senescence in premalignant tumours. Nature 2005, 436:642.
12. Lazzerini Denchi E., Attwooll C., Pasini D., Helin K. Deregulated E2F activity induces hyperplasia and senescence-like features in the mouse pituitary gland. Mol Cell Biol 2005, 25:2660-2672.
13. Michaloglou C., Vredeveld L.C., Soengas M.S., Denoyelle C., Kuilman T., van der Horst C.M., et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005, 436:720-724.
14. Dankort D., Filenova E., Collado M., Serrano M., Jones K., McMahon M. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev 2007, 21:379-384.
15. Dhomen N., Reis-Filho J.S., da Rocha Dias S., Hayward R., Savage K., Delmas V., et al. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 2009, 15:294-303.
16. Sarkisian C.J., Keister B.A., Stairs D.B., Boxer R.B., Moody S.E., Chodosh L.A. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol 2007, 9:493-505.
17. Hydbring P., Bahram F., Su Y., Tronnersjo S., Hogstrand K., von der Lehr N., et al. Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation. Proc Natl Acad Sci USA 2010, 107:58-63.
18. Mallette F.A., Gaumont-Leclerc M.F., Huot G., Ferbeyre G. Myc down-regulation as a mechanism to activate the Rb pathway in STAT5A-induced senescence. J Biol Chem 2007, 282:34938-34944.
19. Ruggero D., Montanaro L., Ma L., Xu W., Londei P., Cordon-Cardo C., et al. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 2004, 10:484-486.
20. Wu C.H., van Riggelen J., Yetil A., Fan A.C., Bachireddy P., Felsher D.W. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci USA 2007, 104:13028-13033.
21. Zhuang D., Mannava S., Grachtchouk V., Tang W.H., Patil S., Wawrzyniak J.A., et al. C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells. Oncogene 2008, 27:6623-6634.
22. Hydbring P., Larsson L.G. Tipping the balance: Cdk2 enables Myc to suppress senescence. Cancer Res 2010, 70:6687-6691.
23. Jiang Z., Zacksenhaus E. Activation of retinoblastoma protein in mammary gland leads to ductal growth suppression, precocious differentiation, and adenocarcinoma. J Cell Biol 2002, 156:185-198.
24. Burkhart D.L., Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer 2008, 8:671-682.
25. Beausejour C.M., Krtolica A., Galimi F., Narita M., Lowe S.W., Yaswen P., et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J 2003, 22:4212-4222.
26. Cobrinik D. Pocket proteins and cell cycle control. Oncogene 2005, 24:2796-2809.
27. Sage J., Miller A.L., Perez-Mancera P.A., Wysocki J.M., Jacks T. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature 2003, 424:223-228.
28. Wang H., Mannava S., Grachtchouk V., Zhuang D., Soengas M.S., Gudkov A.V., et al. c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle. Oncogene 2008, 27:1905-1915.
29. Chicas A., Wang X., Zhang C., McCurrach M., Zhao Z., Mert O., et al. Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence. Cancer Cell 2010, 17:376-387.
30. Rayman J.B., Takahashi Y., Indjeian V.B., Dannenberg J.H., Catchpole S., Watson R.J., et al. E2F mediates cell cycle-dependent transcriptional repression in vivo by recruitment of an HDAC1/mSin3B corepressor complex. Genes Dev 2002, 16:933-947.
31. Nielsen S.J., Schneider R., Bauer U.M., Bannister A.J., Morrison A., O'Carroll D., et al. Rb targets histone H3 methylation and HP1 to promoters. Nature 2001, 412:561-565.
32. Trimarchi J.M., Lees J.A. Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol 2002, 3:11-20.
33. Talluri S., Isaac C.E., Ahmad M., Henley S.A., Francis S.M., Martens A.L., et al. A G1 checkpoint mediated by the retinoblastoma protein that is dispensable in terminal differentiation but essential for senescence. Mol Cell Biol 2010, 30:948-960.
34. Narita M., Nunez S., Heard E., Lin A.W., Hearn S.A., Spector D.L., et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 2003, 113:703-716.
35. Reimann M., Lee S., Loddenkemper C., Dorr J.R., Tabor V., Aichele P., et al. Tumor stroma-derived TGF-beta limits myc-driven lymphomagenesis via Suv39h1-dependent senescence. Cancer Cell 2010, 17:262-272.
36. Steele-Perkins G., Fang W., Yang X.H., Van Gele M., Carling T., Gu J., et al. Tumor formation and inactivation of RIZ1, an Rb-binding member of a nuclear protein-methyltransferase superfamily. Genes Dev 2001, 15:2250-2262.
37. Land H., Parada L.F., Weinberg R.A. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 1983, 304:596-602.
38. van Riggelen J., Muller J., Otto T., Beuger V., Yetil A., Choi P.S., et al. The interaction between Myc and Miz1 is required to antagonize TGFbeta-dependent autocrine signaling during lymphoma formation and maintenance. Genes Dev 2010, 24:1281-1294.
39. Campaner S., Doni M., Hydbring P., Verrecchia A., Bianchi L., Sardella D., et al. Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nat Cell Biol 2010, 12(54-59 Suppl.):1-14.
40. Grandori C., Wu K.J., Fernandez P., Ngouenet C., Grim J., Clurman B.E., et al. Werner syndrome protein limits MYC-induced cellular senescence. Genes Dev 2003, 17:1569-1574.
41. Post S.M., Quintas-Cardama A., Terzian T., Smith C., Eischen C.M., Lozano G. p53-dependent senescence delays Emu-myc-induced B-cell lymphomagenesis. Oncogene 2010, 29:1260-1269.
42. Zou X., Ray D., Aziyu A., Christov K., Boiko A.D., Gudkov A.V., et al. Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence. Genes Dev 2002, 16:2923-2934.
43. Rane S.G., Cosenza S.C., Mettus R.V., Reddy E.P. Germ line transmission of the Cdk4(R24C) mutation facilitates tumorigenesis and escape from cellular senescence. Mol Cell Biol 2002, 22:644-656.
44. Sotillo R., Dubus P., Martin J., de la Cueva E., Ortega S., Malumbres M., et al. Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors. EMBO J 2001, 20:6637-6647.
45. Puyol M., Martin A., Dubus P., Mulero F., Pizcueta P., Khan G., et al. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 2010, 18:63-73.
46. Haas K., Johannes C., Geisen C., Schmidt T., Karsunky H., Blass-Kampmann S., et al. Malignant transformation by cyclin E and Ha-Ras correlates with lower sensitivity towards induction of cell death but requires functional Myc and CDK4. Oncogene 1997, 15:2615-2623.
47. Karsunky H., Geisen C., Schmidt T., Haas K., Zevnik B., Gau E., et al. Oncogenic potential of cyclin E in T-cell lymphomagenesis in transgenic mice: evidence for cooperation between cyclin E and Ras but not Myc. Oncogene 1999, 18:7816-7824.
48. Peeper D.S., Shvarts A., Brummelkamp T., Douma S., Koh E.Y., Daley G.Q., et al. A functional screen identifies hDRIL1 as an oncogene that rescues RAS-induced senescence. Nat Cell Biol 2002, 4:148-153.
49. Macias E., Kim Y., Miliani de Marval P.L., Klein-Szanto A., Rodriguez-Puebla M.L. Cdk2 deficiency decreases ras/CDK4-dependent malignant progression, but not myc-induced tumorigenesis. Cancer Res 2007, 67:9713-9720.
50. Larsson L.G., Henriksson M.A. The Yin and Yang functions of the Myc oncoprotein in cancer development and as targets for therapy. Exp Cell Res 2010, 316:1429-1437.
51. Meyer N., Penn L.Z. Reflecting on 25 years with MYC. Nat Rev Cancer 2008, 8:976-990.
52. Miliani de Marval P.L., Macias E., Rounbehler R., Sicinski P., Kiyokawa H., Johnson D.G., et al. Lack of cyclin-dependent kinase 4 inhibits c-myc tumorigenic activities in epithelial tissues. Mol Cell Biol 2004, 24:7538-7547.
53. Sherr C.J, Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999, 13:1501-1512.
54. Gil J., Peters G. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat Rev Mol Cell Biol 2006, 7:667-677.
55. Kim W.Y., Sharpless N.E. The regulation of INK4/ARF in cancer and aging. Cell 2006, 127:265-275.
56. Brookes S., Rowe J., Ruas M., Llanos S., Clark P.A., Lomax M., et al. INK4a-deficient human diploid fibroblasts are resistant to RAS-induced senescence. EMBO J 2002, 21:2936-2945.
57. Krimpenfort P., Quon K.C., Mooi W.J., Loonstra A., Berns A. Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature 2001, 413:83-86.
58. Takeuchi S., Takahashi A., Motoi N., Yoshimoto S., Tajima T., Yamakoshi K., et al. Intrinsic cooperation between p16INK4a and p21Waf1/Cip1 in the onset of cellular senescence and tumor suppression in vivo. Cancer Res 2010, 70:9381-9390.
59. Schmitt C.A., Fridman J.S., Yang M., Lee S., Baranov E., Hoffman R.M., et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002, 109:335-346.
60. Sharpless N.E., Bardeesy N., Lee K.H., Carrasco D., Castrillon D.H., Aguirre A.J., et al. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 2001, 413:86-91.
61. Haferkamp S., Becker T.M., Scurr L.L., Kefford R.F., Rizos H. p16INK4a-induced senescence is disabled by melanoma-associated mutations. Aging Cell 2008, 7:733-745.
62. McConnell B.B., Starborg M., Brookes S., Peters G. Inhibitors of cyclin-dependent kinases induce features of replicative senescence in early passage human diploid fibroblasts. Curr Biol 1998, 8:351-354.
63. Serrano M., Gomez-Lahoz E., DePinho R.A., Beach D., Bar-Sagi D. Inhibition of ras-induced proliferation and cellular transformation by p16INK4. Science 1995, 267:249-252.
64. Itahana K., Zou Y., Itahana Y., Martinez J.L., Beausejour C., Jacobs J.J., et al. Control of the replicative life span of human fibroblasts by p16 and the polycomb protein Bmi-1. Mol Cell Biol 2003, 23:389-401.
65. Jacobs J.J, Kieboom K., Marino S., DePinho R.A., van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 1999, 397:164-168.
66. Gil J., Bernard D., Martinez D., Beach D. Polycomb CBX7 has a unifying role in cellular lifespan. Nat Cell Biol 2004, 6:67-72.
67. Dietrich N., Bracken A.P., Trinh E., Schjerling C.K., Koseki H., Rappsilber J., et al. Bypass of senescence by the polycomb group protein CBX8 through direct binding to the INK4A-ARF locus. EMBO J 2007, 26:1637-1648.
68. Scott C.L., Gil J., Hernando E., Teruya-Feldstein J., Narita M., Martinez D., et al. Role of the chromobox protein CBX7 in lymphomagenesis. Proc Natl Acad Sci USA 2007, 104:5389-5394.
69. Haupt Y., Alexander W.S., Barri G., Klinken S.P., Adams J.M. Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice. Cell 1991, 65:753-763.
70. van Lohuizen M., Verbeek S., Scheijen B., Wientjens E., van der Gulden H., Berns A. Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell 1991, 65:737-752.
71. Guney I., Wu S., Sedivy J.M. Reduced c-Myc signaling triggers telomere-independent senescence by regulating Bmi-1 and p16(INK4a). Proc Natl Acad Sci USA 2006, 103:3645-3650.
72. Seoane J., Pouponnot C., Staller P., Schader M., Eilers M., Massague J. TGFbeta influences Myc,Miz-1 and Smad to control the CDK inhibitor p15INK4b. Nat Cell Biol 2001, 3:400-408.
73. Staller P., Peukert K., Kiermaier A., Seoane J., Lukas J., Karsunky H., et al. Repression of p15INK4b expression by Myc through association with Miz-1. Nat Cell Biol 2001, 3:392-399.
74. Smith K.S., Chanda S.K., Lingbeek M., Ross D.T., Botstein D., van Lohuizen M., et al. Bmi-1 regulation of INK4A-ARF is a downstream requirement for transformation of hematopoietic progenitors by E2a-Pbx1. Mol Cell 2003, 12:393-400.
75. Smith L.L., Yeung J., Zeisig B.B., Popov N., Huijbers I., Barnes J., et al. Functional crosstalk between Bmi1 and MLL/Hoxa9 axis in establishment of normal hematopoietic and leukemic stem cells. Cell Stem Cell 2011, 8:649-662.
76. Chu I.M., Hengst L., Slingerland J.M. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008, 8:253-267.
77. Alexander K., Hinds P.W. Requirement for p27(KIP1) in retinoblastoma protein-mediated senescence. Mol Cell Biol 2001, 21:3616-3631.
78. Majumder P.K, Grisanzio C., O'Connell F., Barry M., Brito J.M., Xu Q., et al. A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell 2008, 14:146-155.
79. Yung Y., Walker J.L., Roberts J.M., Assoian R.K. A Skp2 autoinduction loop and restriction point control. J Cell Biol 2007, 178:741-747.
80. Kim S.Y., Herbst A., Tworkowski K.A., Salghetti S.E., Tansey W.P. Skp2 regulates Myc protein stability and activity. Mol Cell 2003, 11:1177-1188.
81. von der Lehr N., Johansson S., Wu S., Bahram F., Castell A., Cetinkaya C., et al. The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. Mol Cell 2003, 11:1189-1200.
82. Chandramohan V., Mineva N.D., Burke B., Jeay S., Wu M., Shen J., et al. c-Myc represses FOXO3a-mediated transcription of the gene encoding the p27(Kip1) cyclin dependent kinase inhibitor. J Cell Biochem 2008, 104:2091-2106.
83. Ji P., Jiang H., Rekhtman K., Bloom J., Ichetovkin M., Pagano M., et al. An Rb-Skp2-p27 pathway mediates acute cell cycle inhibition by Rb and is retained in a partial-penetrance Rb mutant. Mol Cell 2004, 16:47-58.
84. Binne U.K., Classon M.K., Dick F.A., Wei W., Rape M., Kaelin W.G., et al. Retinoblastoma protein and anaphase-promoting complex physically interact and functionally cooperate during cell-cycle exit. Nat Cell Biol 2007, 9:225-232.
85. Lin H.K., Chen Z., Wang G., Nardella C., Lee S.W., Chan C.H., et al. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 2010, 464:374-379.
86. Levine A.J., Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009, 9:749-758.
87. Vousden K.H., Lane D.P. p53 in health and disease. Nat Rev Mol Cell Biol 2007, 8:275-283.
88. Alimonti A., Nardella C., Chen Z., Clohessy J.G., Carracedo A., Trotman L.C., et al. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J Clin Invest 2010, 120:681-693.
89. Brown J.P., Wei W., Sedivy J.M. Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. Science 1997, 277:831-834.
90. Harvey M., Sands A.T., Weiss R.S., Hegi M.E., Wiseman R.W., Pantazis P., et al. In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene 1993, 8:2457-2467.
91. Kamijo T., Zindy F., Roussel M.F., Quelle D.E., Downing J.R., Ashmun R.A., et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997, 91:649-659.
92. Pantoja C., Serrano M. Murine fibroblasts lacking p21 undergo senescence and are resistant to transformation by oncogenic Ras. Oncogene 1999, 18:4974-4982.
93. Eischen C.M., Weber J.D., Roussel M.F., Sherr C.J., Cleveland J.L. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 1999, 13:2658-2669.
94. Schmitt C.A., McCurrach M.E., de Stanchina E., Wallace-Brodeur R.R., Lowe S.W. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 1999, 13:2670-2677.
95. Gire V., Wynford-Thomas D. Reinitiation of DNA synthesis and cell division in senescent human fibroblasts by microinjection of anti-p53 antibodies. Mol Cell Biol 1998, 18:1611-1621.
96. Dirac A.M, Bernards R. Reversal of senescence in mouse fibroblasts through lentiviral suppression of p53. J Biol Chem 2003, 278:11731-11734.
97. Grisendi S., Mecucci C., Falini B., Pandolfi P.P. Nucleophosmin and cancer. Nat Rev Cancer 2006, 6:493-505.
98. Herold S., Wanzel M., Beuger V., Frohme C., Beul D., Hillukkala T., et al. Negative regulation of the mammalian UV response by Myc through association with Miz-1. Mol Cell 2002, 10:509-521.
99. Seoane J., Le H.V., Massague J. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 2002, 419:729-734.
100. Wu S., Cetinkaya C., Munoz-Alonso M.J., von der Lehr N., Bahram F., Beuger V., et al. Myc represses differentiation-induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter. Oncogene 2003, 22:351-360.
101. Ventura A., Kirsch D.G., McLaughlin M.E., Tuveson D.A., Grimm J., Lintault L., et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007, 445:661-665.
102. Xue W., Zender L., Miething C., Dickins R.A., Hernando E., Krizhanovsky V., et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007, 445:656-660.
103. Bartkova J., Rezaei N., Liontos M., Karakaidos P., Kletsas D., Issaeva N., et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006, 444:633-637.
104. Di Micco R., Fumagalli M., Cicalese A., Piccinin S., Gasparini P., Luise C., et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006, 444:638-642.
105. Mallette F.A., Gaumont-Leclerc M.F., Ferbeyre G., The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. Genes Dev 2007, 21:43-48.
106. Bartek J., Lukas J. DNA damage checkpoints: from initiation to recovery or adaptation. Curr Opin Cell Biol 2007, 19:238-245.
107. d'Adda di Fagagna F. Living on a break: cellular senescence as a DNA-damage response. Nat Rev Cancer 2008, 8:512-522.
108. Smith J., Tho L.M., Xu N., Gillespie D.A. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res 2010, 108:73-112.
109. Toledo L.I., Murga M., Gutierrez-Martinez P., Soria R., Fernandez-Capetillo O. ATR signaling can drive cells into senescence in the absence of DNA breaks. Genes Dev 2008, 22:297-302.
110. Branzei D., Foiani M. Regulation of DNA repair throughout the cell cycle. Nat Rev Mol Cell Biol 2008, 9:297-308.
111. Lombard D.B., Chua K.F., Mostoslavsky R., Franco S., Gostissa M., Alt F.W. DNA repair, genome stability, and aging. Cell 2005, 120:497-512.
112. Dohi Y., Ikura T., Hoshikawa Y., Katoh Y., Ota K., Nakanome A., et al. Bach1 inhibits oxidative stress-induced cellular senescence by impeding p53 function on chromatin. Nat Struct Mol Biol 2008, 15:1246-1254.
113. Gorrini C., Squatrito M., Luise C., Syed N., Perna D., Wark L., et al. Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response. Nature 2007, 448:1063-1067.
114. Pusapati R.V., Rounbehler R.J., Hong S., Powers J.T., Yan M., Kiguchi K., et al. ATM promotes apoptosis and suppresses tumorigenesis in response to Myc. Proc Natl Acad Sci USA 2006, 103:1446-1451.
115. Reimann M., Loddenkemper C., Rudolph C., Schildhauer I., Teichmann B., Stein H., et al. The Myc-evoked DNA damage response accounts for treatment resistance in primary lymphomas in vivo. Blood 2007, 110:2996-3004.
116. Efeyan A., Murga M., Martinez-Pastor B., Ortega-Molina A., Soria R., Collado M., et al. Limited role of murine ATM in oncogene-induced senescence and p53-dependent tumor suppression. PLoS One 2009, 4:e5475.
117. Gao Y., Sun Y., Frank K.M., Dikkes P., Fujiwara Y., Seidl K.J., et al. A critical role for DNA end-joining proteins in both lymphogenesis and neurogenesis. Cell 1998, 95:891-902.
118. Jeon Y., Ko E., Lee K.Y., Ko M.J., Park S.Y., Kang J., et al. TopBP1 deficiency causes an early embryonic lethality and induces cellular senescence in primary cells. J Biol Chem 2011, 286:5414-5422.
119. Kang J., Bronson R.T., Xu Y. Targeted disruption of NBS1 reveals its roles in mouse development and DNA repair. EMBO J 2002, 21:1447-1455.
120. Morimatsu M., Donoho G., Hasty P. Cells deleted for Brca2 COOH terminus exhibit hypersensitivity to gamma-radiation and premature senescence. Cancer Res 1998, 58:3441-3447.
121. Kumagai A., Lee J., Yoo H.Y., Dunphy W.G. TopBP1 activates the ATR-ATRIP complex. Cell 2006, 124:943-955.
122. Yan S., Michael W.M. TopBP1 and DNA polymerase alpha-mediated recruitment of the 9-1-1 complex to stalled replication forks: implications for a replication restart-based mechanism for ATR checkpoint activation. Cell Cycle 2009, 8:2877-2884.
123. Jeon Y., Lee K.Y., Ko M.J., Lee Y.S., Kang S., Hwang D.S. Human TopBP1 participates in cyclin E/CDK2 activation and preinitiation complex assembly during G1/S transition. J Biol Chem 2007, 282:14882-14890.
124. Liu K., Bellam N., Lin H.Y., Wang B., Stockard C.R., Grizzle W.E., et al. Regulation of p53 by TopBP1: a potential mechanism for p53 inactivation in cancer. Mol Cell Biol 2009, 29:2673-2693.
125. Guerra L., Albihn A., Tronnersjo S., Yan Q., Guidi R., Stenerlow B., et al. Myc is required for activation of the ATM-dependent checkpoints in response to DNA damage. PLoS One 2010, 5:e8924.
126. Luoto K.R., Meng A.X., Wasylishen A.R., Zhao H., Coackley C.L., Penn L.Z., et al. Tumor cell kill by c-MYC depletion: role of MYC-regulated genes that control DNA double-strand break repair. Cancer Res 2010, 70:8748-8759.
127. Robinson K., Asawachaicharn N., Galloway D.A., Grandori C. c-Myc accelerates S-phase and requires WRN to avoid replication stress. PLoS One 2009, 4:e5951.
128. Kobayashi J., Okui M., Asaithamby A., Burma S., Chen B.P., Tanimoto K., et al. WRN participates in translesion synthesis pathway through interaction with NBS1. Mech Ageing Dev 2010, 131:436-444.
129. Deans A.J., Khanna K.K., McNees C.J., Mercurio C., Heierhorst J., McArthur G.A. Cyclin-dependent kinase 2 functions in normal DNA repair and is a therapeutic target in BRCA1-deficient cancers. Cancer Res 2006, 66:8219-8226.
130. Muller-Tidow C., Ji P., Diederichs S., Potratz J., Baumer N., Kohler G., et al. The cyclin A1-CDK2 complex regulates DNA double-strand break repair. Mol Cell Biol 2004, 24:8917-8928.
131. Ismail I.H, Andrin C., McDonald D., Hendzel M.J. BMI1-mediated histone ubiquitylation promotes DNA double-strand break repair. J Cell Biol 2010, 191:45-60.
132. Kaidi A., Weinert B.T., Choudhary C., Jackson S.P. Human SIRT6 promotes DNA end resection through CtIP deacetylation. Science 2010, 329:1348-1353.
133. Liu X., Wang Y., Benaissa S., Matsuda A., Kantarjian H., Estrov Z., et al. Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the antileukemia agent CNDAC. Blood 2010, 116:1737-1746.
134. Sotiropoulou P.A., Candi A., Mascre G., De Clercq S., Youssef K.K., Lapouge G., et al. Bcl-2 and accelerated DNA repair mediates resistance of hair follicle bulge stem cells to DNA-damage-induced cell death. Nat Cell Biol 2010, 12:572-582.
135. Mendes-Pereira A.M., Martin S.A., Brough R., McCarthy A., Taylor J.R., Kim J.S., et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009, 1:315-322.
136. Shen W.H., Balajee A.S., Wang J., Wu H., Eng C., Pandolfi P.P., et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007, 128:157-170.
137. Young A.P., Schlisio S., Minamishima Y.A., Zhang Q., Li L., Grisanzio C., et al. VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. Nat Cell Biol 2008, 10:361-369.
138. Welford S.M., Dorie M.J., Li X., Haase V.H., Giaccia A.J. Renal oxygenation suppresses VHL loss-induced senescence that is caused by increased sensitivity to oxidative stress. Mol Cell Biol 2010, 30:4595-4603.
139. Skoulidis F., Cassidy L.D., Pisupati V., Jonasson J.G., Bjarnason H., Eyfjord J.E., et al. Germline Brca2 heterozygosity promotes Kras(G12D) -driven carcinogenesis in a murine model of familial pancreatic cancer. Cancer Cell 2010, 18:499-509.
140. Nardella C., Clohessy J.G., Alimonti A., Pandolfi P.P. Pro-senescence therapy for cancer treatment. Nat Rev Cancer 2011, 11:503-511.
141. Roberson R.S., Kussick S.J., Vallieres E., Chen S.Y., Wu D.Y. Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. Cancer Res 2005, 65:2795-2803.
142. te Poele R.H., Okorokov A.L., Jardine L., Cummings J., Joel S.P. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 2002, 62:1876-1883.
143. Haugstetter A.M., Loddenkemper C., Lenze D., Grone J., Standfuss C., Petersen I., et al. Cellular senescence predicts treatment outcome in metastasised colorectal cancer. Br J Cancer 2010, 103:505-509.
144. Soucek L., Whitfield J., Martins C.P., Finch A.J., Murphy D.J., Sodir N.M., et al. Modelling Myc inhibition as a cancer therapy. Nature 2008, 455:679-683.
145. Felsher D.W. Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit?. Cancer Res 2008, 68:3081-3086. [discussion 6].
146. Weinstein I.B., Joe A.K. Mechanisms of disease: oncogene addiction-a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 2006, 3:448-457.
147. Wang H., Hammoudeh D.I., Follis A.V., Reese B.E., Lazo J.S., Metallo S.J., et al. Improved low molecular weight Myc-Max inhibitors. Mol Cancer Ther 2007, 6:2399-2408.
148. Delmore J.E., Issa G.C., Lemieux M.E., Rahl P.B., Shi J., Jacobs H.M., et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011, 146:904-917.
149. Mertz J.A., Conery A.R., Bryant B.M., Sandy P., Balasubramanian S., Mele D.A., Targeting MYC, et al. dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci USA 2011, 108:16669-16674.
150. Soucy T.A., Smith P.G., Milhollen M.A., Berger A.J., Gavin J.M., Adhikari S., et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009, 458:732-736.
151. Bykov V.J., Issaeva N., Shilov A., Hultcrantz M., Pugacheva E., Chumakov P., et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002, 8:282-288.
152. Issaeva N., Bozko P., Enge M., Protopopova M., Verhoef L.G., Masucci M., et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 2004, 10:1321-1328.
153. Vassilev L.T. MDM2 inhibitors for cancer therapy. Trends Mol Med 2007, 13:23-31.
154. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303:844-848.
155. Wiman K.G. Pharmacological reactivation of mutant p53: from protein structure to the cancer patient. Oncogene 2010, 29:4245-4252.
156. Wang H., Bauzon F., Ji P., Xu X., Sun D., Locker J., et al. Skp2 is required for survival of aberrantly proliferating Rb1-deficient cells and for tumorigenesis in Rb1+/- mice. Nat Genet 2010, 42:83-88.
157. Kaelin W.G. Synthetic lethality: a framework for the development of wiser cancer therapeutics. Genome Med 2009, 1:99.